New Product ApprovalZynrelef's recent approval of the vial access needle and potential launch of a prefilled syringe could provide near- and mid-term catalysts.
Product DifferentiationZynrelef’s differentiated profile, 72-hour pain relief, and opioid-sparing outcomes could make it the product of choice in the post-surgical pain market.
Strong Financial PerformanceHRTX shares reacted positively due to strength of the top-line and the increase in 2025 adjusted EBITDA guidance range.